OpenEvidence, Memorial Sloan Kettering Cancer Center partner to bring precision oncology AI to more doctors
OpenEvidence and Memorial Sloan Kettering Cancer Center partnered to advance precision oncology AI using agentic AI systems—specialized AI agents that can function as subspecialists in different clinical areas. The collaboration aims to develop what OpenEvidence calls 'medical super-intelligence.'
Why it matters
This partnership demonstrates how AI agents can be deployed to improve cancer diagnosis and treatment by combining deep medical expertise with computational analysis at scale.



